PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision.
Isaacs
Richard J
RJ
Frampton
Christopher M
CM
Kuper-Hommel
Marion J J
MJ
D000911:Antibodies, Monoclonal / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D004345:Drug Industry / Q000191:economics*; D005260:Female; D006801:Humans; D009520:New Zealand; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab